Skip to main content

Table 1 CYP27A1 gnomAD variants

From: Allelic prevalence and geographic distribution of cerebrotendinous xanthomatosis

Variant type

All

N (%)

ClinV-P

N (%)

SeqCon-P

N (%)

Revel-P

N (%)

Model

N (%)

Missense

344 (39.8)

13 (3.8)

–

28 (8.1)

41 (11.9)

Intron

232 (26.9)

–

–

–

–

Synonymous

139 (16.1)

–

–

–

–

Splice_region

35 (4.1)

–

–

–

–

Frameshift

31 (3.6)

12 (38.7)

17 (54.8)

–

29 (93.5)

Stop_gained

23 (2.7)

11 (47.8)

10 (43.5)

–

21 (91.3)

5_prime_UTR

20 (2.3)

–

–

–

–

3_prime_UTR

18 (2.1)

–

–

–

–

Splice_donor

8 (0.9)

5 (62.5)

3 (37.5)

–

8 (100)

Inframe_deletion

4 (0.5)

–

–

–

0 (0. 0)

Splice_acceptor

4 (0.5)

3 (75.0)

1 (25.0)

–

4 (100)

Start_lost

3 (0.3)

–

3 (100)

–

3 (100)

Inframe_insertion

2 (0.2)

–

–

–

–

Stop_retained

1 (0.1)

–

–

–

–

Total

864 (100)

44 (5.1)

34 (3.9)

28 (3.2)

106 (12.3)

  1. Variant count breakdown by type: all gnomAD variants (All), designated pathogenic based on ClinVar clinical significance label (ClinV-P); considered pathogenic based on sequence consequence (SeqCon-P); predicted pathogenic based on REVEL analysis (Revel-P), and final list of variants selected for the prevalence calculation (Model)